Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Pharma & Biotech
Pharma & Biotech
Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.